Abstract: The present disclosure provides for antibody or antigen-binding fragments thereof that bind to human 4Ig-B7H3, multispecific antibody or antigen-binding fragments thereof that recognize human 4Ig-B7H3 as one antigen and at least one other antigen, anti-human 4Ig-B7H3 antibodies or antigen-binding fragments thereof further conjugated with a cytotoxin, a pharmaceutical composition comprising said antibodies or antigen-binding fragments thereof, and use of the antibody, multispecific antibody or the composition for treating a disease, such as cancer.

Abstract: A semiconductor structure and a formation method therefor. The semiconductor structure comprises: a substrate, which has opposite first and second surfaces, and comprises several discrete active areas arranged in a first direction and parallel to a second direction, wherein the first direction is perpendicular to the second direction; word line gate structures, which are disposed in the active areas, extend from the first surface to the second surface, are arranged in the second direction, and run through the active areas along the first direction; a first isolation structure, which is disposed in the substrate and extends from the second surface to the first surface; bit line structures, which are disposed on the first surface, electrically coupled with the active areas, arranged in the first direction, and parallel to the second direction; and capacitor structures, which are disposed on the second surface and electrically coupled with the active areas.

Abstract: Provided herein are compounds, pharmaceutical compositions, and methods for treating a SARS-CoV-2 infection.

Abstract: Described herein are PHD inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of anemia.

Abstract: Provided for compounds and methods for modulating or inhibiting CBL-B.

Abstract: Provided herein are anti-apoptotic BCL-2 family protein degraders, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a disorder, disease, or condition mediated by an anti-apoptotic BCL-2 family protein.

Abstract: Provided are FGFR2 and FGFR3 inhibitors of Formula (I) and pharmaceutical compositions comprising said inhibitors. The compounds and compositions are useful for the treatment of a disease or disorder associated with FGFR2 and/or FGFR3.

Abstract: Described herein are KIF18A inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with KIF18A.

Abstract: Anti-PVRIG antibodies and antigen-binding fragments thereof, are provided, as are related compositions and methods. The antibodies of the disclosure bind to human PVRIG receptor and can block the interaction between the PVRL2 ligand on one cell with PVRIG on an immune cell.

Abstract: The disclosure relates to the field of electric vehicles, and in particular provides a vehicle refrigerator control method, a storage medium, and a vehicle, aiming to solve the problems of how to implement the intelligent identification of items stored in a vehicle refrigerator, and of controlling the vehicle refrigerator based on information of the stored item and vehicle state information. To this end, the method of the disclosure includes: obtaining item information of a vehicle refrigerator; obtaining a real-time temperature and a target temperature of the vehicle refrigerator; obtaining vehicle state information; and controlling the vehicle refrigerator based on the real-time temperature, the target temperature, and the vehicle state information.

Abstract: Described herein are DGKalpha inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with DGKalpha.

Abstract: Provided herein are FAK degraders, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a disorder, disease, or condition mediated by an FAK.

Abstract: Providing compounds of Formula (A) or pharmaceutically acceptable salts, solvate, stereoisomer, or isotopic variant thereof useful as PKMYT1 inhibitors, pharmaceutical compositions comprising the same, and use thereof in the manufacture of medicaments for treating PKMYT1-associated diseases or conditions such as advanced solid tumor, and etc.

Abstract: Described herein are PKMYT1 (Myt1) inhibitors and pharmaceutical compositions comprising said inhibitors. The compounds and compositions are useful for the treatment of a disease or disorder associated with PKMYT1.

Abstract: Described herein are PKMYT1 (Myt1) inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with PKMYT1.

Abstract: A 3D printing system and method for mitigating the force needed to separate a transparent printing membrane from a most-recently photocured layer of resin on a sample secured to a platform. The membrane is coupled to an actuator and a pivot joint adapted to rotate the membrane into the resin, and the platform is coupled to a vertical stage adapted to translate the platform downward. Through simultaneous activation of the actuator and the vertical stage, the membrane is progressively peeled away from the sample. The system and method are suitable for various membrane-based 3D printing technologies including large-area projection micro stereolithography (P?SL).

Abstract: The present invention discloses a pyrimidine heterocyclic compound, and a preparation method and medical use thereof. Specifically, the present invention discloses a pyrimidine heterocyclic compound with a structure shown in Formula (A) or a pharmaceutically acceptable salt thereof (groups are each defined in the specification), a pharmaceutical composition comprising the compound, and use of the compound in treatment of cell proliferative diseases (such as cancers).

Abstract: Described herein are PKMYT1 (Myt1) inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with PKMYT1.

Abstract: Described herein are PKMYT1 (Myt1) inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with PKMYT1.

Abstract: Example three-dimensional (3D) memory devices, methods, and memory systems for connecting vertical transistors and capacitors using connect structures are disclosed. One example method includes forming a first structure that includes multiple vertical transistors. A connect layer is formed over the first structure. The connect layer is etched to form connect structures, where each of the connect structures is coupled to a corresponding one of the vertical transistors. Multiple capacitors are formed over the connect layer, where each of the plurality of capacitors is coupled to a respective connect structure.